Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Topical Minoxidil in Adults 65 and Older: Geriatric Transition and Ongoing Care

By
Published Updated Last reviewed
9 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Regulatory status / Over-the-counter 2% and 5% products [6]
  • Older-adult dose / None listed; directions do not change at 65 [1][2]
  • Men's 5% solution / 1 mL twice daily, vertex only, men only [1]
  • Women's 5% foam / Half a capful once daily [2]
  • Label warnings / Heart disease listed; stop-use symptoms include chest pain, rapid heartbeat, faintness, dizziness, sudden weight gain, hand or foot swelling [1][2]
  • Trial ages / 18 to 49 in the three topical trials discussed [3][4][5]
  • Time to results / 2 to 4 months for men; 3 to 6 months for women [1][2]

Is there a different dose after 65?

No. The labels list no upper age limit and no separate older-adult directions; the only age line is a lower limit of 18 [1][2]. Directions vary by product and sex, not by age.

Men's 5% solution: 1 mL twice a day onto the vertex, men only, not for frontal baldness or a receding hairline [1]. Women's 5% foam: half a capful once daily [2]. The labels say that using more or more often will not improve results and that continued use is necessary or hair loss will begin again [1][2].

What the labels list for older adults

The topical Drug Facts list heart disease under warnings. They list chest pain, rapid heartbeat, faintness or dizziness, sudden unexplained weight gain, swelling of the hands or feet, scalp irritation or redness, and unwanted facial hair growth as reasons to stop use [1][2]. They also say external use only, avoid eye contact, the solution is flammable and the foam extremely flammable, and not to use on a red, inflamed, infected, irritated or painful scalp or with other scalp medicines [1][2].

How strong is the evidence over 65?

The topical trials summarized here enrolled younger adults, and none enrolled adults over 49:

  • A 48-week double-blind trial of 393 men aged 18 to 49 found 5% solution beat 2% solution and placebo for nonvellus hair count, with more itching at 5% [3].
  • A 48-week trial of 381 women aged 18 to 49 found 5% solution superior to placebo on all three primary measures [4].
  • A 16-week trial of 352 men aged 18 to 49 found higher hair counts with 5% foam than placebo (P<.0001), with no efficacy data past 16 weeks [5].

A 2024 oral-versus-topical trial enrolled men aged 18 to 55 [9]. The label timings are the practical guide: results may occur at 2 months for men on twice-daily use and some need at least 4 months, while women using once-daily foam may see results at 3 months and some need 6 [1][2].

Solution or foam?

Men's 5% solution is 1 mL twice daily [1]; a 5% foam has also been studied in men [5]. In a 24-week trial of 113 women, once-daily 5% foam was noninferior to twice-daily 2% solution for nonvellus hair count and produced significantly less local intolerance, especially itching and dandruff (P=.046) [7]. The studied foam is propylene glycol-free [5].

Does anything change at a geriatric visit?

Not on the product side: there is no separate formulation, strength or dosing schedule for older adults, and the labeled directions describe no taper [1][2]. Topical minoxidil has been sold without a prescription since the Rx-to-OTC switch approved 02/09/1996 [6]. The label lists heart disease among its warnings and says not to use it with other scalp medicines [1].

Frequently asked questions

Is topical minoxidil 5% safe for a 70-year-old?
The labels give no separate dose for adults 65 and older, and the topical trials summarized here enrolled adults aged 18 to 49, so they do not establish how well the product works or is tolerated after 65. The labels list heart disease under warnings and list chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain and swelling of the hands or feet as stop-use symptoms [1][2][3][4][5].
Does the 5% solution work on a receding hairline?
The men's 5% solution label covers the vertex only and states it is not intended for frontal baldness or a receding hairline [1].
Can a woman over 65 use 5% foam?
The women's 5% foam label directs half a capful once daily, with results at about 3 months and up to 6 months for some women [2]. The 5% solution is labeled for men only [1].
How long before judging results?
The labels give 2 months for men on twice-daily use, up to 4 months for some, and 3 months for women on once-daily foam, up to 6 months for some [1][2].
Is the foam gentler on the scalp?
The studied foam contains no propylene glycol [5]. In a 24-week trial of 113 women, once-daily 5% foam was noninferior to twice-daily 2% solution for hair count and produced significantly less local intolerance, particularly itching and dandruff (P=.046) [7].

References

  1. U.S. National Library of Medicine, DailyMed. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue prescribing information. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue label
  2. U.S. National Library of Medicine, DailyMed. Women's Rogaine minoxidil 5% topical foam, Kenvue prescribing information. Women's Rogaine minoxidil 5% topical foam, Kenvue label
  3. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men
  4. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss
  5. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-74. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men
  6. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  7. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126-1134.e2. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women
  8. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  9. Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol. 2024;160(6):600-605. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial
Evidence overview for age v2 topical minoxidil: Topical Minoxidil in Adults 65 and Older: Geriatric Transition and Ongoing Care